avdoralimab

BIOLOGICAL2 trials

Sponsors

Centre Leon Berard, Assistance Publique Hopitaux De Marseille

Conditions

Advanced or Metastatic Hematological or Solid TumorCOVIDSARS-CoV-2 (COVID-19) Infection

Phase 2

Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection

CompletedNCT04333914

Centre Leon BerardAdvanced or Metastatic Hematological or Solid Tumor, SARS-CoV-2 (COVID-19) Infection

Start: 2020-04-15End: 2021-12-31Updated: 2022-09-30

Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )

CompletedNCT04371367

Assistance Publique Hopitaux De MarseilleCOVID

Start: 2020-04-27End: 2021-03-30Updated: 2021-05-27

Related Papers

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

Critical Care Medicine2022-10-1026 citations

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

2020-09-28149 citations